Patent · US Active

Cyclic ureas used as inhibitors of metalloproteases

US7652143B2 · kind B2 · utility

0Cited by

4References

2Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Andreas Lindenschmidt · Bad Soden, DE
Holger Wagner · Mettenberg, DE
Jochen Beninga · Mainz, DE
Sven Grueneberg · Kelkheim, DE
Klaus-Ulrich Weithmann · Hofheim, DE

Key dates

Filing date	Jun 15, 2007
Grant date	Jan 26, 2010
Priority date	—
Expiry date	Jun 15, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D405/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a novel compound of the formula I:and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-α converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.